- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07591428
Reset Challenge: Reducing High-risk Drinking for Cancer Prevention
24 giugno 2026 aggiornato da: University of Oklahoma
Feasibility and Preliminary Efficacy of a 30-Day Reset Challenge
This is a single-arm, non-randomized, prospective study to evaluate the feasibility and preliminary efficacy of a 30-day mobile Health (mHealth) Reset Challenge for reducing high-risk drinking.
Panoramica dello studio
Stato
Reclutamento
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Alcohol is a modifiable risk factor for gastrointestinal and breast cancers, with heavy, binge, and daily drinking increasing cancer risk.
To reduce these cancers, accessible, effective, and scalable alcohol interventions are needed.
Mobile Health (mHealth) platforms are well suited for this purpose, as they can screen for high-risk drinking and deliver on-demand, evidence-based interventions directly to at-risk individuals.
Building on the success of the 'Dry January' community intervention, the current study will develop and test a 30-day Reset Challenge.
This trial will recruit 150 adults with high-risk drinking behaviors in Oklahoma and pursue three aims.
First, the investigators aim to evaluate the feasibility and preliminary effectiveness of the Reset Challenge.
Secondly the investigators want to evaluate whether improving confidence in alcohol cessation methods is associated with a higher likelihood of achieving 30-day abstinence.
The exploratory third goal is to examine the feasibility of using an alcohol sensor as an objective outcome measure in a subsample of participants.
To date, "Dry January" community interventions have only minimally investigated treatment mechanisms, and their outcomes have been assessed solely through self-reported alcohol use.
Findings from the current study will determine the feasibility and preliminary efficacy of the Reset Challenge and clarify the potential role of self-efficacy as a critical predictor for successful abstinence.
This work will provide foundational data for future large-scale trials aimed at reducing high-risk drinking, and ultimately lowering alcohol-related cancer in the U.S.
Tipo di studio
Interventistico
Iscrizione (Stimato)
150
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Sophia You, PhD, ABPP
- Numero di telefono: 918-660-3923
- Email: Dokyoung-You@ou.edu
Backup dei contatti dello studio
- Nome: Jordan Keast, BS
- Email: jordan-keast@ou.edu
Luoghi di studio
-
-
Oklahoma
-
Tulsa, Oklahoma, Stati Uniti, 74135
- Reclutamento
- University of Oklahoma Schusterman Center - Tulsa
-
Contatto:
- Jordan Keast, BS
- Email: jordan-keast@ou.edu
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Descrizione
Inclusion Criteria:
- Adults +18
- Individuals who drink alcohol regularly
- Further inclusion criteria will be determined via a Zoom screening with a member of the research staff.
- Current Oklahoma Resident
Exclusion Criteria:
- Exclusion criteria will be determined via a Zoom screening with a member of the research staff.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: 30-Day Reset
Participants will take part in a 30-day alcohol abstinence challenge.
For 2 weeks before, and during the challenge participants will fill out daily surveys monitoring alcohol consumption.
Additionally, there will be a longer 1 and 3-month follow-up survey after the completion of the challenge.
|
The 30-Day reset challenge is inspired by community intervention tools like 'Dry January'.
Throughout the month long trial period, participants will be asked to abstain from alcohol consumption entirely.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility of intervention based on rate of accrual with eligible participant population
Lasso di tempo: From completion of the pre-screening survey to enrollment in the study. On average, no more than two weeks.
|
Rate of study participation among eligible population that completes the screening survey.
≥50% of eligible individuals will enroll in the study
|
From completion of the pre-screening survey to enrollment in the study. On average, no more than two weeks.
|
|
Feasibility of intervention based on rate of completion amongst enrolled participants
Lasso di tempo: From enrollment to 3 months after the completion of the 30-Day Reset Challenge. On average, about four months, depending on the participant's selected start date.
|
Rate of completion among enrolled participants.
≥80% of enrolled participants will complete the study
|
From enrollment to 3 months after the completion of the 30-Day Reset Challenge. On average, about four months, depending on the participant's selected start date.
|
|
Feasibility of intervention based on efficient accrual
Lasso di tempo: From the opening of the studies accrual to 12 months later.
|
Amount of participants recruited to the study in a 12 month period.
A total of 150 participants will be recruited within 12 months
|
From the opening of the studies accrual to 12 months later.
|
|
Efficacy of intervention based on reported alcohol abstinence
Lasso di tempo: From 2 weeks before the participant selected challenge start date to the end of the 30-day reset challenge. Exactly 44 days.
|
Percentage of patients that report abstaining from alcohol throughout the duration of the study.
≥ 60% of participants will abstain from alcohol during the challenge
|
From 2 weeks before the participant selected challenge start date to the end of the 30-day reset challenge. Exactly 44 days.
|
|
Efficacy of intervention based on the weekly alcohol consumption of participants
Lasso di tempo: From the time the participant completes the baseline survey to the completion of the 30-day challenge period. On average, about two months, depending on the participant's selected start date.
|
The average rate of weekly alcohol consumption reported by participants throughout the duration of the study.
Rates of alcohol consumption are expected to be maintained or decrease weekly.
|
From the time the participant completes the baseline survey to the completion of the 30-day challenge period. On average, about two months, depending on the participant's selected start date.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Efficacy of intervention base on alcohol abstinence self-efficacy
Lasso di tempo: From the beginning of the 30-day challenge period to the end of the 30-day challenge period. Exactly 30 days.
|
Self-reported confidence in the ability to abstain from alcohol, assessed using a daily rating scale (e.g., 0-10).
Abstinence self-efficacy is expected to be maintained or increase over the duration of the study.
|
From the beginning of the 30-day challenge period to the end of the 30-day challenge period. Exactly 30 days.
|
|
Efficacy of intervention based on reported alcohol use
Lasso di tempo: From the beginning of the 30-day challenge period to the end of the 30-day challenge period. Exactly 30 days.
|
Rate of self-reported alcohol consumption (weekly quantity) in daily survey.
It is expected that rates of consumption will be maintained or decrease throughout the challenge period.
|
From the beginning of the 30-day challenge period to the end of the 30-day challenge period. Exactly 30 days.
|
|
Efficacy of intervention based on sustained abstinence
Lasso di tempo: From completion of the 30-day challenge period to 3 months post-completion of the 30-day challenge period. Exactly 3 months.
|
Rate of self-reported alcohol use (weekly quantity) after completion of 30 day challenge period.
It is expected that rates will be maintained or continue to decrease after the 30 day challenge period
|
From completion of the 30-day challenge period to 3 months post-completion of the 30-day challenge period. Exactly 3 months.
|
|
Efficacy of intervention based on sustained alcohol abstinence self-efficacy
Lasso di tempo: From the completion of the baseline survey to 3 months after the completion of the 30-day challenge period. On average, about 4 months, depending on the participant's selected start date.
|
Reported score of alcohol abstinence self-efficacy given on survey scale (e.g., 1-10) after the challenge period.
It is expected that self-efficacy scoring will be maintained or increase after complete of the 30 day challenge period.
|
From the completion of the baseline survey to 3 months after the completion of the 30-day challenge period. On average, about 4 months, depending on the participant's selected start date.
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Sophia You, PhD, ABPP, University of Oklahoma
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
10 giugno 2026
Completamento primario (Stimato)
1 dicembre 2027
Completamento dello studio (Stimato)
1 aprile 2028
Date di iscrizione allo studio
Primo inviato
28 aprile 2026
Primo inviato che soddisfa i criteri di controllo qualità
12 maggio 2026
Primo Inserito (Effettivo)
15 maggio 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
26 giugno 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
24 giugno 2026
Ultimo verificato
1 giugno 2026
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 19340P
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .